Stereoselective evasion of P-glycoprotein, cytochrome P450 3A, and hydrolases by peptide prodrug modification of saquinavir

Journal of Pharmaceutical Sciences

Volumn 101, Issue 9, 2012, Pages 3199-3213

  Wang, Zhiying ^a   Pal, Dhananjay ^a   Mitra, Ashim K ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

CYP enzymes; Metabolism; P glycoprotein; Peptide transporters; Prodrugs; Stability; Structure activity relationship (SAR)

Indexed keywords

CYTOCHROME P450 3A; GLYCOPROTEIN P; HYDROLASE; SAQUINAVIR; VALINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BIODEGRADATION; CELL MEMBRANE PERMEABILITY; CELL STRAIN CACO 2; CELL TRANSPORT; CONTROLLED STUDY; DRUG CLEARANCE; DRUG HALF LIFE; HUMAN; HUMAN CELL; HYDROLYSIS; LIVER MICROSOME; MALE; NONHUMAN; PLASMA; PROTEIN MODIFICATION; RAT; STEREOCHEMISTRY; TISSUE HOMOGENATE;

EID: 84864075043     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23193     Document Type: Article

References (42)

1. Markowitz M, Saag M, Powderly WG, Hurley AM, Hsu A, Valdes JM, Henry D, Sattler F, La Marca A, Leonard JM. 1995. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 333:1534-1539.
2. Williams GC, Sinko PJ. 1999. Oral absorption of the HIV protease inhibitors: A current update. Adv Drug Del Rev 39:211-238.
3. Figgitt DP, Plosker GL. 2000. Saquinavir soft-gel capsule: An updated review of its use in the management of HIV infection. Drugs 60:481-516.
4. Usansky HH, Hu P, Sinko PJ. 2008. Differential roles of P-glycoprotein, multidrug resistance-associated protein 2, and CYP3A on saquinavir oral absorption in Sprague-Dawley rats. Drug Metab Dispos 36:863-869.
5. Eagling VA, Wiltshire H, Whitcombe IW, Back DJ. 2002. CYP3A4-mediated hepatic metabolism of the HIV-1 protease inhibitor saquinavir in vitro. Xenobiotica 32:1-17.
6. Benet LZ, Kroetz DL, Sheiner LB. 1996. Pharmacokinetics: The dynamics of drug absorption, distribution, and elimination. In Goodman & Gilman's the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, pp 3-27.
7. Parker AJ, Houston JB. 2008. Rate-limiting steps in hepatic drug clearance: Comparison of hepatocellular uptake and metabolism with microsomal metabolism of saquinavir, nelfinavir, and ritonavir. Drug Metab Dispos 36:1375-1384.
8. Decker CJ, Laitiner LM, Bridson GW, Raybuck SA, Tung RD, Chaturredi PR. 1998. Metabolism of amprenavir in liver microsomes: Role of CYP3A4 inhibition for drug interactions. J Pharm Sci 87:803-807.
9. Noble S, Faulds D. 1996. Saquinavir: A review of its pharmacology and clinical potential in the management of HIV infection. Drugs 52:93-112.
10. Perry CM, Noble S. 1998. Saquinavir soft-gel capsule formulation. A review of its use in patients with HIV infection. Drugs 55:461-486.
11. Kumar GN, Rodrigues AD, Buko AM, Denissen JF. 1996. Cytochrome P450 mediated metabolism of the HIV-1 protease inhibitor Ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther 277:23-31.
12. Pal D, Mitra AK. 2006. MDR- and CYP3A4-mediated drug-drug interactions. J Neuroimmune Pharmacol 1:323-339.
13. Kim AE, Dintaman JM, Waddell DS, Silverman JA. 1998. Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein. J Pharmacol Exp Ther 286:1439-1445.
14. Marchetti S, de Vries NA, Buckle T, Bolijn MJ, van Eijndhoven MA, Beijnen JH, Mazzanti R, van Tellingen O, Schellens JH. 2008. Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice. Mol Cancer Ther 7:2280-2287.
15. van Asperen J, van Tellingen O, Sparreboom A, Schinkel AH, Borst P, Nooijen WJ, Beijnen JH. 1997. Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. Br J Cancer 76:1181-1183.
16. Steffansen B, Nielsen CU, Brodin B, Eriksson AH, Andersen R, Frokjaer S. 2004. Intestinal solute carriers: An overview of trends and strategies for improving oral drug absorption. Eur J Pharm Sci 21:3-16.
17. Agarwal S, Boddu SH, Jain R, Samanta S, Pal D, Mitra AK. 2008. Peptide prodrugs: Improved oral absorption of lopinavir, a HIV protease inhibitor. Int J Pharm 359:7-14.
18. Ganapathy ME, Brandsch M, Prasad PD, Ganapathy V, Leibach FH. 1995. Differential recognition of β-lactam antibiotics by intestinal and renal peptide transporters, PEPT 1 and PEPT 2. J Biol Chem 270:25672-25677.
19. Irie M, Terada T, Okuda M, Inui K. 2004. Efflux properties of basolateral peptide transporter in human intestinal cell line Caco-2. Pflugers Arch 449:186-194.
20. Pieri M, Christian HC, Wilkins RJ, Boyd CA, Meredith D. 2010. The apical (hPepT1) and basolateral peptide transport systems of Caco-2 cells are regulated by AMP-activated protein kinase. Am J Physiol Gastrointest Liver Physiol 299:G136-G143.
21. Jain R, Duvvuri S, Kansara V, Mandava NK, Mitra AK. 2007. Intestinal absorption of novel-dipeptide prodrugs of saquinavir in rats. Int J Pharm 336:233-240.
22. Sawada K, Terada T, Saito H, Hashimoto Y, Inui KI. 1999. Recognition of l-amino acid ester compounds by rat peptide transporters PEPT1 and PEPT2. J Pharmacol Exp Ther 291:705-709.
23. Hutt AJ, O'Grady J. 1996. Drug chirality: A consideration of the significance of the stereochemistry of antimicrobial agents. J Antimicrob Chemother 37:7-32.
24. Song H, Griesgraber GW, Wagner CR, Zimmerman CL. 2002. Pharmacokinetics of amino acid phosphoramidate monoesters of zidovudine in rats. Antimicrob Agents Chemother 46:1357-1363.
25. Pochopin NL, Charman WN, Stella VJ. 1994. Pharmacokinetics of dapsone and amino acid prodrugs of dapsone. Drug Metab Dispos 22:770-775.
26. Tamura K, Bhatnagar PK, Takata JS, Lee CP, Smith PL, Borchardt RT. 1996. Metabolism, uptake, and transepithelial transport of the diastereomers of Val-Val in the human intestinal cell line, Caco-2. Pharm Res 13:1213-1218.
27. Talluri RS, Samanta SK, Gaudana R, Mitra AK. 2008. Synthesis, metabolism and cellular permeability of enzymatically stable dipeptide prodrugs of acyclovir. Int J Pharm 361:118-124.
28. König SK, Herzog M, Theile D, Zembruski N, Haefeli WE, Weiss J. 2010. Impact of drug transporters on cellular resistance towards saquinavir and darunavir. J Antimicrob Chemother 65:2319-2328.
29. Jain R, Agarwal S, Majumdar S, Zhu X, Pal D, Mitra AK. 2005. Evasion of P-gp mediated cellular efflux and permeability enhancement of HIV-protease inhibitor saquinavir by prodrug modification. Int J Pharm 303:8-19.
30. Taipalensuu J, Törnblom H, Lindberg G, Einarsson C, Sjöqvist F, Melhus H, Garberg P, Sjöström B, Lundgren B, Artursson P. 2001. Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers. J Pharmacol Exp Ther 299:164-170.
31. Katragadda S, Talluri RS, Mitra AK. 2006. Modulation of P-glycoprotein-mediated efflux by prodrug derivatization: An approach involving peptide transportermediated influx across rabbit cornea. J Ocul Pharmacol Ther 22:110-120.
32. Ganapathy V, Leibach FH. 1996. Peptide transporters. Curr Opin Nephrol Hypertens 5:395-400.
33. Mitsuoka K, Kato Y, Kubo Y, Tsuji A. 2007. Functional expression of stereoselective metabolism of cephalexin by exogenous transfection of oligopeptide transporter PEPT1. Drug Metab Dispos 35:356-362.
34. Lister N, Sykes AP, Bailey PD, Boyd CAR, Bronk JR. 1995. Dipeptide transport and hydrolysis in isolated loops of rat small intestine: Effects of stereospecificity. J Physiol 484:173-182.
35. Fitzsimmons ME, Collins JM. 1997. Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: Potential contribution to high first-pass metabolism. Drug Metab Dispos 25:256-266.
36. Treijtel N, van Eijkeren JC, Nijmeijer S, de Greef-van der Sandt IC, Freidig AP. 2009. Clearance and clearance inhibition of the HIV-1 protease inhibitors ritonavir and saquinavir in sandwich-cultured rat hepatocytes and rat microsomes. Toxicol In Vitro 23:185-193.
37. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, Gunsalus IC, Nebert DW. 1996. P450 superfamily: Update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6:1-42.
38. Michaud V, Simard C, Turgeon J. 2010. Characterization of CYP3A isozymes involved in the metabolism of domperidone: Role of cytochrome b(5) and inhibition by ketoconazole. Drug Metab Lett 4:95-103.
39. Miners JO, Knights KM, Houston JB, Mackenzie PI. 2006. In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: Pitfalls and promises. Biochem Pharmacol 71:1531-1539.
40. Tsume Y, Vig BS, Sun J, Landowski CP, Hilfinger JM, Ramachandran C, Amidon GL. 2008. Enhanced absorption and growth inhibition with amino acid monoester prodrugs of floxuridine by targeting hPEPT1 transporters. Molecules 13:1441-1454.
41. Fang G, Konings WN, Poolman B. 2000. Kinetics and substrate specificity of membrane-reconstituted peptide transporter DtpT of Lactococcus lactis. J Bacteriol 182:2530-2535.
42. Clement JG, Erhardt N. 1990. Serum carboxylesterase activity in various strains of rats: Sensitivity to inhibition by CBDP (2-/o-cresyl/4H:1:3:2-benzodioxaphosphorin-2-oxide). Arch Toxicol 64:414-416.